Loading…
Acumen Pharmaceuticals, Inc. is projected to rise to $2.72 by 2027, a +7% move from its current price of $2.54. ABOS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.46 | $2.54 | $2.63 | 0.00% |
| May 30 | $2.42 | $2.54 | $2.66 | -0.01% |
| May 31 | $2.39 | $2.54 | $2.69 | -0.01% |
| Jun 1 | $2.37 | $2.54 | $2.72 | -0.02% |
| Jun 2 | $2.35 | $2.54 | $2.74 | -0.02% |
| Jun 3 | $2.34 | $2.54 | $2.76 | -0.02% |
| Jun 4 | $2.32 | $2.54 | $2.78 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.32 | $2.54 | $2.78 | -0.03% |
| Week 2 | $2.24 | $2.54 | $2.88 | -0.05% |
| Week 3 | $2.17 | $2.54 | $2.97 | -0.08% |
| Week 4 | $2.12 | $2.54 | $3.04 | -0.11% |
| Week 5 | $2.07 | $2.54 | $3.10 | -0.13% |
| Week 6 | $2.03 | $2.54 | $3.16 | -0.16% |
| Week 7 | $2.00 | $2.54 | $3.22 | -0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of Alzheimer's disease. The lead program sabirnetug (ACU193) is in Phase 2 ALTITUDE-AD to target toxic soluble amyloid beta oligomers.
The company has collaboration and license agreements with Halozyme, Inc. for a subcutaneous formulation of Sabirnetug, and with JCR Pharmaceuticals Co. Ltd for Aß oligomer-targeted enhanced brain delivery therapy.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
This description reflects its healthcare focus and ongoing clinical development efforts, with partnerships designed to advance its candidate therapies in the Alzheimer's disease space. The information provided outlines corporate relationships and location details that characterize its current corporate footprint without delving into unlisted specifics.
ABOS is the ticker used in the healthcare sector, and the stock is positioned within a market cap framework that places it among smaller-cap equities. The details below summarize its current price, market position, and the forecasted path ahead based on the available data.
Acumen Pharmaceuticals, Inc. (ABOS) trades in the healthcare sector with a current price of $2.51 and a market cap of $181.29M. Its market positioning shows a rank of 3895. The asset’s latest price and capitalization place it within the lower end of the market-cap spectrum, reflecting a micro-cap profile within healthcare.
The price outlook from the provided forecast indicates upside potential over multiple years, with calculated averages rising from the 2026 level to substantially higher targets by 2050. The sequence of annual averages and bullish data points suggests a trajectory of cumulative appreciation across the forecast horizon.
Specifically, the year-by-year numbers show a path from a 2026 avg of $2.51 to higher annual averages (e.g., $4.58 by 2030, $10.52 by 2040, and $24.83 by 2050) with corresponding maximums and minimums outlined in the data. These figures imply meaningful long-run upside despite near-term uncertainty.
A major floor 28.7% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
The nearest ceiling, 11.8% above — a clean break opens room to run.
A major ceiling 32.7% above — clearing it would confirm fresh momentum.
Key ABOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.46 | Buy | $2.46 | Buy |
| MA 10 | $2.38 | Buy | $2.43 | Buy |
| MA 20 | $2.43 | Buy | $2.45 | Buy |
| MA 50 | $2.55 | Sell | $2.53 | Buy |
| MA 100 | $2.54 | Sell | $2.46 | Buy |
| MA 200 | $2.16 | Buy | $2.26 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.77 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 77.00 | Neutral |
| Williams %R (14) | -7.50 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -0.78 | Sell |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 92.50 | Sell |
| TRIX (15) | -0.37 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 60.41 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 2.55 | Sell |
| ADX (14) | 12.03 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is mixed but leaning bullish in the near term. The sentiment is described as BULLISH, while the RSI(14) is 50, placing it at a midpoint on momentum. The stock trades around key moving averages, with the SMA50 at $2.59 and the SMA200 at $2.14, indicating a recent crossover dynamic that can support near-term moves.
Support is identified at $2.17 and resistance at $2.84, framing a narrow tactical range. The 30-day range spans from $2.01 to $3.14, offering a defined window for near-term price activity and potential breakout or pullback scenarios within that interval.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.72 | $2.54 | $3.66 | 0% | Neutral | |
| $2.11 | $2.72 | $3.75 | +7% | Neutral | |
| $2.40 | $3.21 | $4.62 | +26% | Bullish | |
| $2.63 | $3.62 | $5.39 | +43% | Bullish | |
| $3.18 | $4.49 | $6.87 | +77% | Bullish | |
| $3.76 | $5.45 | $8.55 | +115% | Bullish | |
| $3.74 | $5.54 | $8.88 | +118% | Bullish | |
| $3.94 | $5.96 | $9.76 | +135% | Bullish | |
| $4.05 | $6.25 | $10.43 | +146% | Bullish | |
| $3.91 | $6.16 | $10.45 | +143% | Bullish | |
| $5.81 | $10.01 | $18.24 | +294% | Bullish | |
| $11.67 | $23.63 | $47.71 | +830% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.72 | $2.54 | $2.98 | +0.00% |
| June 2026 | $2.07 | $2.45 | $2.97 | -3.57% |
| July 2026 | $2.12 | $2.53 | $3.12 | +3.34% |
| August 2026 | $2.20 | $2.64 | $3.30 | +4.38% |
| September 2026 | $2.17 | $2.63 | $3.32 | -0.48% |
| October 2026 | $2.18 | $2.66 | $3.39 | +1.29% |
| November 2026 | $2.28 | $2.80 | $3.60 | +5.14% |
| December 2026 | $2.29 | $2.83 | $3.66 | +0.91% |
Click any year to see its month-by-month ABOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABOS to range from $1.72 to $3.66 through 2026. The $2.54 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABOS price prediction for 2027 points to an average of $2.72 (low $2.11, high $3.75) — a potential gain of +7% on today's $2.54. A consolidation phase looks the most probable path here.
In 2028, ABOS is projected to trade between $2.40 and $4.62, averaging $3.21 — a potential gain of +26% from today's $2.54. That is up +18% on the projected 2027 average. Momentum favours further upside here.
Acumen Pharmaceuticals, Inc.'s 2029 outlook centres on $3.62, within a $2.63 to $5.39 range. That is up +13% on the projected 2028 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ABOS could reach as high as $6.87, with a base case around $4.49 and support toward $3.18 — roughly +77% from $2.54. Momentum favours further upside here.
Expect ABOS to range from $3.76 to $8.55 through 2031. The $5.45 average target implies a +115% move from current prices. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABOS price prediction for 2032 points to an average of $5.54 (low $3.74, high $8.88) — a potential gain of +118% on today's $2.54. Momentum favours further upside here.
In 2033, ABOS is projected to trade between $3.94 and $9.76, averaging $5.96 — a potential gain of +135% from today's $2.54. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Acumen Pharmaceuticals, Inc.'s 2034 outlook centres on $6.25, within a $4.05 to $10.43 range. That is up +5% on the projected 2033 average. That marks a +146% change versus current levels. Momentum favours further upside here.
By 2035, ABOS could reach as high as $10.45, with a base case around $6.16 and support toward $3.91 — roughly +143% from $2.54. Buyers look set to stay in control over this stretch.
Expect ABOS to range from $5.81 to $18.24 through 2040. The $10.01 average target implies a +294% move from current prices. That is up +63% on the projected 2035 average. Momentum favours further upside here.
The ABOS price prediction for 2050 points to an average of $23.63 (low $11.67, high $47.71) — a potential gain of +830% on today's $2.54. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABOS today (≈ 393.700787 ABOS) could be worth
$9,302.21
+$8,302.21 (+830%) by 2050 · US Dollar
Based on the average projected ABOS price of $23.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABOSwould be worth at today's price.
$1,000 invested in ABOS on May 27, 2025 (≈ 980.392175 ABOS) would be worth
$2,490.2
+$1,490.2 (+149.0%) today · 2.49× · US Dollar
Based on a ABOS entry price of $1.02 vs. today's $2.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.35 | $1,080.85 | +8.1% |
| 1 month ago | $2.52 | $1,007.94 | +0.8% |
| 3 months ago | $2.83 | $897.53 | -10.2% |
| 6 months ago | $1.88 | $1,351.06 | +35.1% |
| 1 year ago | $1.02 | $2,490.2 | +149.0% |
| All time (4.9y) ago | $20.1 | $126.37 | -87.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABOS forecast.
Our base-case forecast reaches $5.10 around 2031.
Implied market cap at $5.10: $368.36M
The multi-year forecast shows a bullish trajectory with clear upside through 2030 and beyond. The 2030 average is $4.58, representing an 82.3% return on investment from the baseline values in the forecast. The 2040 average expands to $10.52 with a 319.2% ROI, and by 2050 the average is $24.83 with an 889.4% ROI, underscoring substantial long-run appreciation expectations.
The forecast also provides yearly min/max ranges that illustrate potential volatility, such as 2030 with a min of $3.24 and a max of $7.00, and 2040 with a min of $6.13 and a max of $19.12. While sentiment remains bullish across the later years, these are estimates and not guarantees, and actual results will depend on market conditions and company progress.
Overall, the outlook is bullish over the long horizon, with meaningful upside potential by 2040 and beyond, tempered by the inherent uncertainty of forward-looking projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.58 with a min of $3.24 and a max of $7.00, and a ROI of 82.3%. The sentiment is BULLISH.
The forecast data show a bullish trajectory from 2028 onward, with 2030 avg $4.58 and 2050 avg $24.83, and ROIs up to 889.4%. These are estimates and not guarantees, and individual results may vary.
Yes. The 2040 forecast lists an average of $10.52 and a 2040 max of $19.12, indicating the possibility of exceeding $10 on the path to 2040.
The 2050 forecast shows a max of $49.99 with an average of $24.83 and an ROI of 889.4%, signaling substantial long-run upside.
The 30-day range is from $2.01 to $3.14, with near-term support at $2.17 and resistance at $2.84. The stock currently trades around $2.51, with the SMA50 at $2.59 and SMA200 at $2.14.
Acumen Pharmaceuticals, Inc. Community Discussion
0Share your Acumen Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.